Top Markets
Coin of the day
Allena Pharmaceuticals, Inc. Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc.

ALNAQ
Rang in Aktien #42825
Operating as a biopharmaceutical firm, Allena Pharmaceuticals, Inc. focuses on... Operating as a biopharmaceutical firm, Allena Pharmaceuticals, Inc. focuses on unearthing, developing, and marketing oral enzyme therapies. These treatments are devised to assist patients in the United States afflicted by uncommon and serious metabolic as well as renal conditions. Central to its pipeline is ALLN-346, an innovative enzyme designed to degrade urate, targeting hyperuricemia and gout in individuals with advanced chronic kidney disease. The company, which commenced operations in 2011 and has its main office in Newton, Massachusetts, made headlines on September 2, 2022, by seeking voluntary reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Aktienkurs
$0.000001
Zuletzt synchronisiert: 2023-12-13
Marktkapitalisierung
$23.51
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Allena Pharmaceuticals, Inc. (ALNAQ)

Kategorie

EPS für Allena Pharmaceuticals, Inc. (ALNAQ)
EPS zum 2026 TTM: 0
Laut den aktuellen Finanzberichten und dem Aktienkurs von Allena Pharmaceuticals, Inc. beträgt das aktuelle EPS des Unternehmens (TTM) 0. Am Ende des Jahres 2026 betrug das EPS 0 gleich wie dem EPS von 2026, das 0 betrug.
EPS-Verlauf von Allena Pharmaceuticals, Inc. von 2026 bis 2026
EPS am Ende jedes Jahres
Jahr EPS ändert
Nicht genügend Daten für die angegebenen Daten.
EPS für ähnliche Unternehmen oder Wettbewerber
Unternehmen EPS EPS-Differenz Land
$17.32 -
US
$27.74 -
NL
- -
CH
$13.70 -
BE
- -
KR